Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Barst, B. Brundage, A. Ghofrani, R. Oudiz, G. Simonneau, A. Beardsworth, M. Chan, N. Galie (New York, NY, Bend, OR, Torrance, CA, United States Of America; Giessen, Germany; Clamart, France; Erl Wood, United Kingdom; Danforth, Canada; Bologna, Italy). Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH). Eur Respir J 2008; 32: Suppl. 52, 3176

Member's Comments

No comment yet.

Related content which might interest you: Sitaxsentan for pulmonary arterial hypertension (PAH) patients with clinical deterioration or significantly abnormal liver function test on bosentan Source: Eur Respir J 2005; 26: Suppl. 49, 563s Year: 2005 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Hemodynamics as a substitute for exercise capacity endpoints in patients with pulmonary arterial hypertension (PAH): A model based assessment for sildenafil Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension Source: Eur Respir J 2013; 42: 414-424 Year: 2013 Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary circulation Year: 2007 Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension Source: Eur Respir J 2012; 40: 1410-1419 Year: 2012 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Effect of long-term oxygen therapy on exercise capacity and quality of life in exercise-desaturating patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomized-sham-controlled cross-over trial Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Does sildenafil improves exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Effect of treatment on exercise endurance tolerance and ventilatory efficiency in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Sitaxsentan improves 6MW and hemodynamics in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD) Source: Eur Respir J 2005; 26: Suppl. 49, 564s Year: 2005 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Effect of exercise and respiratory training on time to clinical worsening and survival in patients with severe chronic pulmonary hypertension Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Exercise tolerability in children with pulmonary arterial hypertension (PAH), a population pk/pd assessment of the effects of sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005